Retatrutide vs Mounjaro: Direct Research Comparison for UAE 2026

The Mechanism Difference Matters

Both peptides target gut and CNS receptors that regulate appetite and glucose. The split:

The glucagon agonism is what sets retatrutide apart. Glucagon was historically considered the "bad twin" of insulin — it raises blood glucose. But at controlled doses in the multi-agonist context, it drives energy expenditure (basal metabolic rate up) without producing hyperglycemia because the GLP-1 and GIP components offset glucose effects.

Weight Loss Data Head-to-Head

Retatrutide — Jastreboff 2023 phase 2 (NEJM)

• 338 adults, BMI ≥30 without diabetes
• 48 weeks treatment
• Doses: 1, 4, 8, 12 mg weekly SC
• Weight change at 48 weeks: −24.2% at 12 mg, −22.8% at 8 mg, −17.5% at 4 mg, −8.7% at 1 mg, −2.1% placebo
• Weight loss still trending downward at week 48 — plateau not reached

Tirzepatide (Mounjaro) — SURMOUNT-1 (Jastreboff 2022 NEJM)

• 2,539 adults, BMI ≥30 or ≥27 with comorbidity, without diabetes
• 72 weeks treatment
• Doses: 5, 10, 15 mg weekly SC
• Weight change at 72 weeks: −20.9% at 15 mg, −19.5% at 10 mg, −15.0% at 5 mg, −3.1% placebo
• Plateau approaching by week 60

What this comparison does and doesn't tell us

Different trial lengths, different populations, no head-to-head. But the broad picture: retatrutide at the highest tested dose appears to produce more weight loss faster than tirzepatide at the highest approved dose. Whether this gap holds at 72 weeks — and whether it justifies the side-effect profile — awaits phase 3 retatrutide data (expected 2026–2027).

Side Effects — Both Cause GI Issues, Retatrutide Adds One More

The heart-rate elevation with retatrutide is attributed to the glucagon receptor activity. Phase 2 data showed it was clinically asymptomatic and stable, but phase 3 long-term cardiac monitoring is ongoing.

Practical Dosing — Research Context

Retatrutide protocols in research literature

• Starting dose: 0.5 mg or 1 mg weekly SC
• Titration: increase every 4 weeks if tolerated
• Typical research escalation: 0.5 → 1 → 2 → 4 → 8 → 12 mg
• REVIVE supplies 5 mg and 10 mg vials — see our reconstitution math guide

Tirzepatide protocols

• Approved starting dose: 2.5 mg weekly
• Titration: increase 2.5 mg every 4 weeks
• Maintenance: 5, 10, or 15 mg weekly

UAE Availability and Access

Mounjaro (tirzepatide) is available in UAE pharmacies with prescription. Retatrutide is not approved by any regulator and is only available as a research compound. REVIVE supplies retatrutide 5 mg and 10 mg vials for research-use-only contexts in the UAE — see our retatrutide catalogue.

Pricing comparison per mg of active peptide favours research-grade retatrutide significantly, but the regulatory and clinical-supervision differences are substantial. See our UAE peptide market overview for tier-by-tier pricing.

Decision Framework

1. If you need an approved, prescribable medicine: Mounjaro is the only option of the two.
2. If you're running peptide research and want maximum weight-loss data: Retatrutide has the higher phase 2 effect size.
3. If you want fastest weight reduction in a research timeframe: Retatrutide reaches deeper losses faster.
4. If you want the longest safety record: Tirzepatide has more years of human data.